PHD, CBO, EpiCypher
Biography
Dr. Martis Cowles is a scientist / entrepreneur focused on the democratization and scaling of ultra-sensitive chromatin profiling technologies to unlock the full potential of epigenomics for drug development and clinical research. He first joined EpiCypher to lead their non-dilutive fund-raising efforts, which has been widely successful - securing >$45M in funding to support new technology development. Currently, Dr. Cowles leads EpiCyphers business segment, which oversees fund raising, partnering, licensing, and IP. Martis earned his PhD from the University of California San Diego, studying transcriptional networks that control adult neurogenesis and brain patterning. Prior to joining EpiCypher, Dr. Cowles studied developmental signaling pathways that underlie cortical stem cell function in the developing mouse brain.
Talk
Clinical & Research Tools Showcase:
EpiCypher
EpiCypher continuously pushes technology boundaries to deliver innovative products and services to epigenetics and chromatin biology researchers. From our strong scientific expertise and rigor to our focus on customer success, EpiCypher is proud to be an epigenetics company For Scientists, By Scientists.
Leverage quantitative epigenomics for PM
EpiCypher's CUTANA® CUT&RUN/Tag technology is revolutionizing how epigenetic biomarkers can be identified for accelerated drug development.
Session Abstract – PMWC 2023 Silicon Valley
Showcase Track S2 - January 25 2.45 P.M.-4.00 P.M.,Showcase Track S2 - January 26 1.30 P.M.-4.00 P.M.,Showcase Track S2 - January 27 1.15 P.M.-1.30 P.M.
The PMWC 2023 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
